Definition of Somatic Variants Corresponding to Immune Targets in Patients with Metastatic Melanoma
Objective
To determine the feasibility of the detection and characterization of novel epitopes in FFPE tissues using adjacent normal tissues as controls To determine if there are differences in the epitope expression between responders (long term survivors) and non-responders (rapid progressors) to immune therapy To determine if there are differences in known genes of known importance to immunotherapies such as MHC Class I expression, PD-1L1, PD1-L2 expression and other phenotypes on immunohistochemical assays
